ARON 3D_Transparent

Publications

All our publications
non clear

Immune-based Combinations in Intermediate-/Poor-risk Patients with Non-clear Cell RenalCell Carcinoma: Results from the ARON-1 Study

Massari F
, et al. Eur Urol Focus
2025
Cabo nivo vs pembro axi 1

Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients withmetastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1)

Santoni M
Cancer Immunol Immunother.
2025
Geo diff

Geographical Differences in the Management and Outcomes of PatientsWith Advanced Urothelial Carcinoma Treated With Pembrolizumab AfterProgression on Platinum-Based Chemotherapy: Results From ARON-2Study

Rizzo M,
JCO Glob Oncol.
2025
MOUSEION 010

Nutritional conditions and PFS and OS in cancer immunotherapy: the MOUSEION-010 meta-analysis

Vitale E
et al. Immunotherapy
2025
Concomitant Med ARON 2

Concomitant medications in patients with metastatic urothelial carcinoma receiving enfortumab vedotin: real-world data from the ARON-2EV study

Fiala O
et al. Clin Exp Metastasis
2025
Sequences ARON 2

Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective Experience

Rizzo M
et al. Cancer Med
2025

Do you want to join us ?

Join us today
ARON 3D_Transparent
Youtube Linkedin

Coordinated and designed by Atteggiamento Digitale .

Legal and Privacy.